- Home
- AARD vs TARA Comparison
AARD vs TARA Comparison
Compare AARD & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- TARA
- Stock Information
- Founded
- AARD 2017
- TARA N/A
- Country
- AARD United States
- TARA United States
- Employees
- AARD N/A
- TARA N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AARD Health Care
- TARA Health Care
- Exchange
- AARD Nasdaq
- TARA Nasdaq
- Market Cap
- AARD 154.9M
- TARA 126.5M
- IPO Year
- AARD 2025
- TARA N/A
- Fundamental
- Price
- AARD $13.77
- TARA $2.86
- Analyst Decision
- AARD Strong Buy
- TARA Strong Buy
- Analyst Count
- AARD 5
- TARA 7
- Target Price
- AARD $33.00
- TARA $20.67
- AVG Volume (30 Days)
- AARD 77.3K
- TARA 452.7K
- Earning Date
- AARD 08-14-2025
- TARA 08-05-2025
- Dividend Yield
- AARD N/A
- TARA N/A
- EPS Growth
- AARD N/A
- TARA N/A
- EPS
- AARD N/A
- TARA N/A
- Revenue
- AARD N/A
- TARA N/A
- Revenue This Year
- AARD N/A
- TARA N/A
- Revenue Next Year
- AARD N/A
- TARA N/A
- P/E Ratio
- AARD N/A
- TARA N/A
- Revenue Growth
- AARD N/A
- TARA N/A
- 52 Week Low
- AARD $4.88
- TARA $1.60
- 52 Week High
- AARD $19.58
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- TARA 43.02
- Support Level
- AARD N/A
- TARA $3.12
- Resistance Level
- AARD N/A
- TARA $3.10
- Average True Range (ATR)
- AARD 0.00
- TARA 0.19
- MACD
- AARD 0.00
- TARA -0.01
- Stochastic Oscillator
- AARD 0.00
- TARA 17.19
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).